A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post ...

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with ...

Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.